The Joint Blog

JANUARY 31, 2021

The study is titled A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extract as complementary therapy: A case report. For the study researchers studied the effects of marijuana extracts in a fifteen-year-old who suffered from autism, anxiety, and controlled epilepsy. Case presentation.

Epilepsy 62

Epilepsy Extraction Research and Development Clinical Trials 62

CannaTech

SEPTEMBER 16, 2018

Similar frameworks exist across the world, presenting the same set of challenges Canada has faced along the way. But this gap restricts patient access to a medicine that can offer relief to a long list of conditions including chronic pain, seizures attributed to epilepsy, as well as mood disorders such as anxiety and depression.

Education 66

Education Medicine Clinical Trials Patients 66

Cannabis Law Report

OCTOBER 1, 2021

Mack will present an overview of Virpax and take part in a fireside chat moderated by Noble Capital Markets senior equity research analyst, Gregory Aurand at the Pain Management Virtual Investor Forum on Thursday, October 7, 2021 at 9:00 a.m. Eastern time. www.youtube.com/channelchek. About Virpax Pharmaceuticals.

Research and Development 40

Research and Development Pharmaceutical Clinical Trials Chronic Pain 40

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. The perception that CBD is a wonder-drug version of cannabis — particularly known for its uses to treat epilepsy — that doesn’t get you high.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

JANUARY 26, 2022

The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need. No drug is without risks, so clinical trials have included careful investigation of possible adverse effects.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

The Joint Blog

JANUARY 23, 2020

. “Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known.”

Clinical Trials 52

Clinical Trials Marijuana Sleep Cannabinoids 52

Cannabis Law Report

OCTOBER 5, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021. The Company’s presentation will be available for viewing that day at 10:10 a.m.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Media 40

Cannabis Law Report

OCTOBER 19, 2021

Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m. ET in Track 1. MyMD Chief Scientific Officer Adam Kaplin, M.D.,

Pharmaceutical 40

Pharmaceutical Therapy Clinical Trials Chronic Pain 40

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD’s superior potency over CBD by factor of 8,000 times. “We

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

Cannabis Law Report

NOVEMBER 1, 2021

The substance is allowed in Hong Kong as long as other prohibited ingredients derived from cannabis are not present in the products. A 2018 report by the World Health Organization said CBD showed no indication of potential abuse or dependence, and in fact it had been found in several clinical trials to be effective in treating epilepsy.

Wellness and Beauty 52

Wellness and Beauty CBD Clinical Trials Pharmaceutical 52

Cannabis Law Report

DECEMBER 1, 2021

Format: Presentation and 1×1 meetings (virtual). Presentation time: Wednesday, December 8 at 4:00 p.m. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. Date: December 2, 2021. Format: 1-on-1 meetings (virtual).

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Therapy 40

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Epidiolex is a CBD-infused oral-based medication designed to help patients as young as two-years-old treat epilepsy disorders.

Research and Development 40

Research and Development Epilepsy Clinical Trials Treatment 40

Otherside Farms

APRIL 14, 2020

In another study, people dealing with epilepsy were given 200-300mg of CBD daily and began to experience fewer seizures. Presently, Charlotte Figi enjoys a healthier life with here seizures cut down drastically to nearly 2 episodes in a month, down from approximately 300 a week. In June of 2019, the FDA in the U.S.

CBD 52

CBD Research and Development Sleep Clinical Trials 52

Cannabis Law Report

SEPTEMBER 1, 2019

The Victorian and New South Wales Governments had both begun clinical trials of cannabis products for children with severe epilepsy and for palliative care, respectively. Fast forward to the present day. The clinical trials and the standard of production could lead the world.”.

Clinical Trials 53

Clinical Trials Research and Development Medicine Cultivation 53

Cannabis Law Report

JANUARY 13, 2020

Justin Gover, GW’s Chief Executive Officer expects to discuss these updates as part of a webcast presentation at the 38 th Annual J.P. Nabiximols (known as “Sativex” outside US) in the US: Commence pivotal clinical program in initial target indication of spasticity associated with Multiple Sclerosis. 14th at 11:00 a.m. PT (2:00 p.m.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Cannabis Law Report

DECEMBER 7, 2021

This trend is also observed in the pediatric population, where MCs are authorized in children for refractory epilepsy, especially in Dravet syndrome and Lennox-Gastaut syndrome 2. Therefore, a summary table of adverse mental events is presented with Conditional maximum likelihood estimate of Rate Ratio and Fischer exact test 46.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

OCTOBER 26, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Dr. Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

MMJ Recs

JULY 5, 2024

It is one of over 100 cannabinoids present in cannabis, and it is responsible for the “high” or euphoric sensation typically associated with cannabis use. Neurological Disorders Research suggests THC may benefit neurological conditions such as epilepsy, multiple sclerosis (MS), and Parkinson’s disease. What is THC?

THC 52

THC Research and Development Chronic Pain Cannabinoids 52

Cannabis Law Report

NOVEMBER 15, 2021

Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. VRP324 represents our first CNS disorder product indication. On September 9, 2021, Jeffrey A. Forward-Looking Statement.

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

DECEMBER 21, 2019

Following the success showed in treating epilepsy with cannabis a lot of experts have been fully invested in the possibilities of treating autism with the plant. In the past year alone several institutions have talked about the clinical trials they have underway to determine the specific effects of CBD on autism patients.

Research and Development 45

Research and Development CBD Conditions Therapy 45

MMJ Recs

DECEMBER 22, 2023

Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders. Peer-reviewed studies, clinical trials, and meta-analyses have played a crucial role in dispelling myths and misconceptions surrounding medical marijuana.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Investor Presentation Information. Eleusis and Silver Spike have prepared a prerecorded investor presentation.

Therapy 40

Therapy Research and Development Business Access 40

Cannabis Law Report

NOVEMBER 24, 2021

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Refractory paediatric epilepsy. Conclusions. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ).

Research and Development 52

Research and Development Medicine Access Media 52

Veriheal

AUGUST 31, 2020

It brings us great pleasure to present the 10 winners of Veriheal’s Innovation in Cannabis Scholarship 2020. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death.

Research and Development 119

Research and Development Education Agriculture Patients 119

Cannabis Law Report

APRIL 10, 2019

MP Philippa Whitford (representing Central Ayrshire ), a doctor, called for more support for clinical trials so that doctors will be more willing to prescribe medical cannabis products: “That is quite scary for doctors, particularly as if it is an unlicensed drug, they have to sign a form to say that they accept personal liability.

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

Kind Meds (Cannabis Education Blog)

NOVEMBER 16, 2022

Unlike some other cannabinoids, it is not present in substantial amounts in fresh cannabis flower. As mentioned, CBN is also not present in therapeutic amounts in most cannabis flower. CBN is believed to relieve symptoms of conditions in which seizures are a symptom, including epilepsy. CBN Sleep Products and More.

Sleep 94

Sleep Cannabinoids THC CBD 94

Canna Law Blog

APRIL 17, 2020

Below are five things I learned about Hemp CBD for pet products in preparing for my presentation at CBD Considerations in the Northwest. THC binds to the CB1 receptors, but the way that CBD interacts with ECS is not fully understood in humans or animals, despite the fact that Epidiolex has been approved as a drug for treating epilepsy.

Pets 74

Pets Hemp CBD Food 74

Greencamp

AUGUST 16, 2018

The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies). Exploring the available research on ALS and cannabinoids.

Strains 94

Strains Cannabinoids Research and Development Indica 94

SMPL

MAY 26, 2020

Within a couple of years, they figured out a 1:1 combination of a high-THC chemovar and a high-CBD chemovar presented the greatest latitude of effects and prevention of side effects,” said Dr. Ethan Russo, who worked with GW Pharmaceuticals from 1998 to 2014. fast-tracked clinical trials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

Green Relief

MAY 13, 2018

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. It is the most commonly identified cause of epilepsy among adults. CBD produces no intoxicating effects, no THC -like high, and its use does not lead to tolerance.

THC 64

THC CBD Cannabinoids Research and Development 64

Green Relief

MAY 12, 2018

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. It is the most commonly identified cause of epilepsy among adults. CBD produces no intoxicating effects, no THC -like high, and its use does not lead to tolerance.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

Cannabis Law Report

DECEMBER 30, 2019

State lawmakers passed Assembly Bill 420 , which authorizes the University of California’s Center for Medicinal Cannabis Research to cultivate cannabis for clinical trials. Specifically, it expands the pool of patients eligible for cannabis therapy to include those with chronic pain, menstrual cramps, and epilepsy.

Legislation 45

Legislation Patients Access Banking 45

Cannabis Law Report

AUGUST 12, 2019

Broad spectrum oil — An oil rich in CBD and the beneficial cannabinoids and terpenes present in hemp EXCEPT for THC. After multiphase clinical trials were completed, an FDA panel recommended approval of a CBD-based pharmaceutical called Epidiolex for treatment of certain specific and rare types of juvenile epilepsy.

CBD 40

CBD Terpenes Oil Tincture 40

Cannabis Law Report

OCTOBER 17, 2019

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. This is true even if the CBD comes from industrial hemp.

Law 40

Law Seed-To-Sale Hemp Recreational 40

Veriheal

NOVEMBER 7, 2024

Because the categorization of a controlled substance determines its availability and accessibility, the benefits of rescheduling are important to patients suffering from chronic pain, epilepsy, and other conditions. The December 2 hearing represents a critical juncture in this years-long rescheduling process.

DEA 97

DEA Policy Chronic Pain Marijuana 97